Trial · NCT07476729
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729, Phase 3, Recruiting, Charite University, Berlin, Germany
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020). Trials, record NCT07476729. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07476729
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
- NCT number
- NCT07476729
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 750 participants, estimated
- Lead sponsor
- Charite University, Berlin, Germany
- Conditions
- B-Cell Acute Lymphoblastic Leukaemia
- Interventions
- Inotuzumab ozogamicin (INO), Blinatumomab
- First posted
- 2026-03-17
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | SR induction EFS | From enrollment until 2 years after end of treatment | timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | SR-MRD good response consolidation DFS | From enrollment until 2 years after end of treatment | timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | HR with CR2 consolidation DSF | From enrollment until 2 years after end of treatment | timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | Isolated extramedullary manifestations: EFS | From enrollment until 2 years after end of treatment | timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up |
| Primary | SR induction: Pharmacokinetics Inotuzumab | from enrollment until day 28 | cumulative area under the concentration-time curve (AUC) |
| Secondary | SR induction: MRD | Day 28 of induction | MRD negativity rate after induction quantified by flow- and/or PCR techniques |
| Secondary | SR-MRD good response consolidation: OS | From enrollment until 2 years after end of treatment | timespan of survival until death or until end of follow up |
| Secondary | Isolated extramedullary manifestations: EFS | From enrollment until 2 years after end of treatment | timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up |
| Secondary | SR induction: allo-HSCT | week 14 to 20 after enrollment | Proportion of patients requiring allo-HSCT |
| Secondary | SR induction: OS | from enrollment until 2 years after end of treatment | timespan of survival until death or until end of follow up |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers18
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07476729
GET https://conductscience.org/api/trials/v1/NCT07476729/registered?page=2